at 1 mg L-1; followed by the treatment A2, containing BAP
(1.0 mg L-1) in combination with KIN (0.1 mg L-1) and AIA
(0.2 mg L-1) (17.2 shoots/explant per month). In the A4
treatment, a more compact structure was formed; in the
control (A5), the multiplication coefficient was the lowest
(1.79 shoots/explant per month) (Figs. 2 and 3).